BioSpace News Archive

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 3 EXPLORER-HCM clinical trial.

New Board Members Bring More Than 50 Years of Combined Technology Experience to the Council’s Prestigious Board

From battlefield to bedside, these rugged and reliable solutions have ushered in a new era of helping clinicians bring ultrasound to any patient, anywhere, anytime.

Boston-based XenoTherapeutics Aims to Bring Life-Saving Innovation from The Lab to Address the Global Shortage of Transplantable Organs and Tissues.

The U.S. Food and Drug Administration was notified by Bayer that the Essure permanent birth control device will no longer be sold or distributed after December 31, 2018.

Technavio has announced their latest pipeline analysis report on the polycystic ovary syndrome market.

Technavio has announced their latest pipeline analysis report on the retinitis pigmentosa market.

Progress in treating acute myeloid leukemia (AML), a blood cancer that takes more than 10,000 lives in the United States each year, took an important step forward today with the U.S. Food & Drug Administration (FDA) approval of ivosidenib (Tibsovo®) for patients who have a specific genetic mutation called IDH1.

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the design of its pivotal Phase 3 EXPLORER-HCM clinical trial to evaluate the use of mavacamten for the potential treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of its investigational drug, mavacamten.